2020
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant
Fabrizio VA, Kernan NA, Boulad F, Cancio M, Allen J, Higman M, Margossian SP, Mauguen A, Prockop S, Scaradavou A, Shah N, Spitzer B, Stieglitz E, Yeager N, O’Reilly R, Brentjens RJ, Jan Boelens J, Curran KJ. Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplantation 2020, 55: 2160-2169. PMID: 32390002, PMCID: PMC7606268, DOI: 10.1038/s41409-020-0926-1.Peer-Reviewed Original ResearchConceptsCAR T cellsAllo-HSCTT cellsCumulative incidenceCell transplantAllogeneic hematopoietic stem cell transplantAllogeneic hematopoietic cell transplantHematopoietic stem cell transplantCAR T-cell therapyConsolidative allo-HSCTHematopoietic cell transplantYoung adult patientsFavorable overall survivalStem cell transplantT-cell therapyFavorable OSOverall survivalAdult patientsSevere toxicitySmall cohortDisease controlPatientsCD34IncidenceRelapse
2018
106 Survival Trends after Allogeneic Hematopoietic Cell Transplant (HCT) in Children Less Than One-Year-Old (Infants)
Parikh S, Ahn K, Sahr N, Zhu X, Abraham A, Auletta J, Chhabra S, Copelan E, Dvorak C, Fretham C, Gadalla S, Gale R, Gergis U, Heimatti P, Hildebrandt G, Keating A, Myers K, Savani B, Shah N, Pasquini M, Satwani P. 106 Survival Trends after Allogeneic Hematopoietic Cell Transplant (HCT) in Children Less Than One-Year-Old (Infants). Transplantation And Cellular Therapy 2018, 24: s116. DOI: 10.1016/j.bbmt.2017.12.032.Peer-Reviewed Original ResearchHematopoietic cell transplantAllogeneic hematopoietic cell transplantCell transplantSurvival trendsOne-yearTransplant